Company Overview
Snapshot
Founded in April 2014 by Amir Bahar and Nora Nseir, Nurami Medical operates with 11–50 employees. The company has raised $43.65 million across 9 funding rounds from 11 investors. In August 2023, Nurami Medical's ArtiFascia®.
Business overview
Nurami Medical develops advanced regenerative solutions for soft tissue repair, leveraging proprietary nanofibers and novel biomaterials. The company's electrospun-based platform technology creates innovative bio-surgical implants designed to effectively seal and heal wounds, addressing complications associated with current soft tissue implants and promoting healthy tissue formation. Its flagship product, ArtiFascia, is a multilayer dural repair graft made of biocompatible and bioabsorbable polymers, engineered to promote neodura regeneration. Nurami Medical serves the medical devices and biotechnology sectors, with a focus on neurosurgery and regenerative medicine, and its products are commercially available in the USA.
Strategic signal
Nurami Medical announced the successful completion of Phase 1 milestones in an EIC-backed grant for its ArtiFix Dural Repair Graft in November 2025. This achievement signals continued progress in the development of its regenerative solutions for soft tissue repair, validating the company's R&D capabilities and its potential to bring innovative medical devices to market with support from European innovation programs.
Log in to access full profile ›Company Intelligence Q&A
- What was a key regulatory achievement for Nurami Medical?
- In August 2023, Nurami Medical's ArtiFascia® Dura Substitute received FDA Clearance, enabling its commercial use in the USA.
- What is the status of Nurami Medical's EIC-backed grant?
- In November 2025, Nurami Medical announced the successful completion of Phase 1 milestones in its EIC-backed grant for the ArtiFix Dural Repair Graft.
- Who was appointed Chairman of Nurami Medical?
- In May 2022, Peter Stebbins was appointed Chairman of Nurami Medical.